Propargylamine: an important moiety in drug discovery - Supplementary Figures

Supplementary Figure 1. Chemical structures of the FDA-approved drugs rasagiline and

selegiline/deprenyl.

Supplementary Figure 2. Metabolic pathways that propargylamine derivatives may undergo within the

body according to different publications in the literature [8,9].

Supplementary Figure 3. Proposed mechanism of activation of propargylamine-based MAO inhibitors by

Albreht et al. [26].

Supplementary Figure 4. Propargylamine-based radioligands for PET imaging of MAO-A and MAO-B

highlighted in the work by Narayanaswami et al. [33].

Supplementary Figure 5. Chemical structure of ladostigil, a propargylamine-based clinical candidate that

acts as a MAO and AChE–BuChE dual inhibitor.

Supplementary Figure 6. General scheme of the copper-catalyzed azide–alkyne cycloaddition (CuAAC),

one of the most used bioorthogonal click chemistry reactions [69].